Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 27;14(15):3646.
doi: 10.3390/cancers14153646.

Diagnosis and Treatment of Pineal Region Tumors in Adults: A EURACAN Overview

Affiliations
Review

Diagnosis and Treatment of Pineal Region Tumors in Adults: A EURACAN Overview

Giuseppe Lombardi et al. Cancers (Basel). .

Abstract

Pineal region tumors are rare intracranial tumors, accounting for less than 1% of all adult intracranial tumor lesions. These lesions represent a histologically heterogeneous group of tumors. Among these tumors, pineal parenchymal tumors and germ cell tumors (GCT) represent the most frequent types of lesions. According to the new WHO 2021 classification, pineal parenchymal tumors include five distinct histotypes: pineocytoma (PC), pineal parenchymal tumors of intermediate differentiation (PPTID), papillary tumor of the pineal region (PTPR), pinealoblastoma (PB), and desmoplastic myxoid tumor of the pineal region, SMARCB1-mutant; GCTs include germinoma, embryonal carcinoma, yolk sac tumor, choriocarcinoma, teratoma, mixed GCTs. Neuroradiological assessment has a pivotal role in the diagnostic work-up, surgical planning, and follow-up of patients with pineal masses. Surgery can represent the mainstay of treatment, ranging from biopsy to gross total resection, yet pineal region tumors associated with obstructive hydrocephalus may be surgically managed via ventricular internal shunt or endoscopic third ventriculostomy. Radiotherapy remains an essential component of the multidisciplinary treatment approach for most pineal region tumors; however, treatment volumes depend on the histological subtypes, grading, extent of disease, and the combination with chemotherapy. For localized germinoma, the current standard of care is chemotherapy followed by reduced-dose whole ventricular irradiation plus a boost to the primary tumor. For pinealoblastoma patients, postoperative radiation has been associated with higher overall survival. For the other pineal tumors, the role of radiotherapy remains poorly studied and it is usually reserved for aggressive (grade 3) or recurrent tumors. The use of systemic treatments mainly depends on histology and prognostic factors such as residual disease and metastases. For pinealoblastoma patients, chemotherapy protocols are based on various alkylating or platinum-based agents, vincristine, etoposide, cyclophosphamide and are used in association with radiotherapy. About GCTs, their chemosensitivity is well known and is based on cisplatin or carboplatin and may include etoposide, cyclophosphamide, or ifosfamide prior to irradiation. Similar regimens containing platinum derivatives are also used for non-germinomatous GCTs with very encouraging results. However, due to a greater understanding of the biology of the disease's various molecular subtypes, new agents based on targeted therapy are expected in the future. On behalf of the EURACAN domain 10 group, we reviewed the most important and recent developments in histopathological characteristics, neuro-radiological assessments, and treatments for pineal region tumors.

Keywords: EURACAN; pineal region tumors; pinealoblastoma; rare tumors.

PubMed Disclaimer

Conflict of interest statement

G.L. declares funding for a consulting or advisory role from Bayer, AbbVie, Orbus Therapeutics, BrainFarm, Health4U, Novartis, and Janssen, and funding for travel from Roche, Bayer, and Ipsen. ET declares funding for a consulting or advisory role from Gliocure, AstraZeneca and funding for travel from Novocure. V.Z. declares funding for a consulting or advisory role from Bristol-Myers Squibb and Merck, speakers’ bureau funding from Bayer, Roche, Bristol-Myers Squibb, Astellas Pharma, Servier, AstraZeneca, and Lilly, and funding for travel and accommodation from Bayer, Roche, and Servier. MW has received research grants from Apogenix and Quercis, and honoraria for lectures or advisory board participation or consulting from Bayer, Medac, Merck (EMD), Nerviano Medical Sciences, Novartis, Orbus, Philogen and y-Mabs; AI declares Research grants from Carthera, Transgene, Sanofi, Air Liquide, Servier, Nutritheragene, advisory board for Leo Pharma, Novocure and Boehringer Ingelheim Int, travel funding from Novocure, Carthera and Leo Pharma outside the submitted work. P.L.P., R.M., M.B., G.M., E.R., G.C. have no conflict of interest to declare.

Figures

Figure 1
Figure 1
Summary of the Pineal Region Tumors according to the WHO 2021 classification.
Figure 2
Figure 2
Surgical approaches to pineal region tumors: Endoscopic transventricular third ventriculostomy and biopsy with CSF sampling (A), interhemispheric parietal approach (B), suboccipital transtentorial approach (C), and supracerebellar infratentorial approach (D).

Similar articles

Cited by

References

    1. Goschzik T., Gessi M., Denkhaus D., Pietsch T. PTEN Mutations and Activation of the PI3K/Akt/MTOR Signaling Pathway in Papillary Tumors of the Pineal Region. J. Neuropathol. Exp. Neurol. 2014;73:747–751. doi: 10.1097/NEN.0000000000000093. - DOI - PubMed
    1. Gheban B.A., Rosca I.A., Crisan M. The Morphological and Functional Characteristics of the Pineal Gland. Med. Pharm. Rep. 2019;92:226–234. doi: 10.15386/mpr-1235. - DOI - PMC - PubMed
    1. Kong Z., Wang Y., Dai C., Yao Y., Ma W., Wang Y. Central Nervous System Germ Cell Tumors: A Review of the Literature. J. Child Neurol. 2018;33:610–620. doi: 10.1177/0883073818772470. - DOI - PubMed
    1. Palmisciano P., Ogasawara C., Nwagwu C.D., Bin Alamer O., Gupta A.D., Giantini-Larsen A.M., Scalia G., Yu K., Umana G.E., Cohen-Gadol A.A., et al. Metastases in the Pineal Region: A Systematic Review of Clinical Features, Management Strategies, and Survival Outcomes. World Neurosurg. 2022;159:156–167.e2. doi: 10.1016/j.wneu.2022.01.005. - DOI - PMC - PubMed
    1. Tan X., Xiao M., Jiang W., Yue C., Qu L., Zhao G. Paediatric Atypical Teratoid/Rhabdoid Tumour of the Pineal Region Mimicking a Meningioma: A Case Report and Literature Review. Br. J. Neurosurg. 2021;16:1–4. doi: 10.1080/02688697.2021.1895971. - DOI - PubMed

LinkOut - more resources